PhenoVista Biosciences Partners with NETRI
PhenoVista Biosciences, a prominent contract research organization (CRO) based in San Diego, has entered into an exciting partnership with NETRI, renowned for its manufacturing of microfluidic devices aimed at high-throughput screening (HTS). This collaboration is set to enhance their service offerings related to organ-on-chip technology, an innovative method crucial in drug development and healthcare applications.
The Power of Collaboration
With NETRI’s expertise in creating sophisticated organ-on-chip devices combined with PhenoVista’s extensive background in biologically intricate, in vitro models, this partnership represents a leap forward in the drug discovery process. NETRI is committed to making organ-on-chip technology more widely accessible, which is evidenced by their expanding portfolio of products that cater to oncology and various neurobiological domains.
Transformative Applications in Healthcare
NETRI’s innovative models address various crucial health issues, including chemotherapy-induced peripheral neuropathy (CIPN) and applications within dermatology and cosmetology. Most recently, NETRI has been developing platforms that focus on neuromuscular junctions, which play a significant role in understanding diseases and developing effective therapies. These advanced models not only compartmentalize cells effectively but also support high-throughput screening, enhancing the ability to conduct complex biological assays.
Enhancing Drug Development
PhenoVista specializes in providing disease-relevant, cell-based assay services. They engage with clients collaboratively, ensuring that the assays are not only physiologically relevant but also adaptable to ongoing research needs. With a solid reputation among biopharmaceutical clients, PhenoVista prides itself on delivering high-quality data through its unique cellular models combined with state-of-the-art high-content imaging technologies.
Commitment to Quality and Innovation
Clients of PhenoVista benefit from a diverse range of services, from pre-designed assays to fully customized solutions tailored to specific research objectives. By utilizing primary cells, iPSC-derived neurons, and engineered cell lines, PhenoVista ensures that their assays meet the diverse needs of modern drug development.
Dr. Thierry Poumeyrol, Chief Business Officer of NETRI, shares enthusiasm for the collaboration, stating, “Our mission has always been centered on democratizing advanced organ-on-chip technologies to bolster advancements in drug discovery and healthcare. Joining forces with PhenoVista marks a significant progression towards realizing that vision.”
James Evans, co-founder and CEO of PhenoVista, adds, “This collaboration aligns perfectly with our mission to provide scientists with impactful data regarding drug efficacy and mechanisms of action. The seamless integration of NETRI's microfluidic platform with our imaging and assay capabilities will undoubtedly enhance our clients’ research outcomes.”
Expediting Drug Discovery
This partnership aims to empower the biopharmaceutical industry with enhanced, functional assays that accelerate drug development initiatives. The unique combination of NETRI’s cell-culture technologies and PhenoVista’s capability in high-content assay development is set to furnish researchers with unprecedented tools to speed up the drug discovery process effectively.
Frequently Asked Questions
What is the focus of the partnership between PhenoVista and NETRI?
The partnership aims to integrate NETRI's advanced organ-on-chip technologies with PhenoVista's expertise in high-content imaging to streamline the drug development process.
How will this partnership impact drug discovery?
This collaboration will empower researchers with more relevant and functional assays, facilitating faster discovery and development of new therapeutic solutions.
What services does PhenoVista provide?
PhenoVista offers a range of disease-relevant, cell-based assay services, including custom and ready-to-use high-content assays for drug development.
What technologies does NETRI specialize in?
NETRI specializes in microfluidic devices for high-throughput screening which are essential for creating detailed organ-on-chip models.
How does this collaboration benefit biopharmaceutical companies?
This partnership provides biopharmaceutical companies access to innovative tools and methodologies that can significantly enhance their research capabilities and patient outcomes.
